JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boerman, O. C.
Right arrow Articles by Corstens, F. H.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boerman, O. C.
Right arrow Articles by Corstens, F. H.M.
Journal of Nuclear Medicine Vol. 42 No. 9 1405-1411
© 2001 by Society of Nuclear Medicine


BASIC SCIENCE INVESTIGATIONS

A 3-Step Pretargeting Strategy to Image Infection

Otto C. Boerman, Julliette van Eerd, Wim J.G. Oyen and Frans H.M. Corstens

Department of Nuclear Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands

A new 3-step approach to imaging infectious and inflammatory foci was developed and optimized in a rat model. The approach relies on the nonspecific localization of an anti-diethylenetriaminepentaacetic acid (DTPA) antibody in inflamed tissue. In this study, the 3-step strategy was optimized by selecting the most suitable radiolabeled hapten and tuning the dosing schedule. Methods: Wistar rats with Staphylococcus aureus infection in the left calf muscle were primed with the anti-DTPA antibody DTIn-1 (0.67, 2, or 6 nmol per rat). In the second step (1–24 h later), the anti-DTPA activity in the circulation was blocked with unlabeled bovine serum albumin DTPA-In (0.3, 1, or 3 nmol per rat). In the third step (5–30 min later), the radiolabeled hapten (monovalent or bivalent 111In-DTPA) was administered. The in vivo distribution of the radiolabel was monitored by scintigraphic imaging and by ex vivo counting of dissected tissues. Results: Scatchard analysis revealed that the affinity of DTIn-1 for bivalent DTPA-111In (111In-diDTPA) was 6 times higher than the affinity for monovalent 111In-DTPA (Ka = 0.87 x 10-9 mol/L vs. 5.3 x 10-9 mol/L). The uptake of the bivalent chelate in the abscess was 2.5-fold higher than that of monovalent 111In-DTPA. Most important, the bivalent chelate was completely retained in the abscess over time. Using the bivalent chelate, the optimal dosing scheme was determined with respect to the DTIn-1 dose (2 nmol per rat), the blocking agent dose (1 nmol per rat), and radiolabeled chelate dose (40 pmol per rat). The procedure was rapid; the infectious focus was clearly visualized 1 h after injection of the 111In-labeled diDTPA, which was 5 h after administration of the anti-DTPA antibody. The nontargeted radiolabel rapidly cleared to the urine, only being retained in the abscess and the kidneys (4–6 percentage injected dose). Finally, an N2S2 core was attached to the diDTPA compound, allowing the use of 99mTc. Conclusion: This 3-step approach enables rapid imaging of infectious foci with minimal uptake in noninflamed tissues.

Key Words: pretargeting • infection imaging • bivalent hapten • anti-DTPA antibody







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.